A randomized, double-blind, placebo-controlled clinical study to evaluate safety and pharmacokinetics of Natrunix-SQ
Latest Information Update: 28 Jan 2022
At a glance
- Drugs Vilamakitug (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- 28 Jan 2022 New trial record
- 26 Jan 2022 According to XBiotech media release, first patient had been enrolled in this study